Q4 2024 Management View CEO Bernard Zovighian highlighted a strong Q4 2024 performance with total company sales growing 9% year-over-year to $1.39 billion and adjusted earnings per share of $0.59. He ...

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices. Investors remain bullish on ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Reports Q4 revenue $1.39B, consensus $1.36B. Q4 TAVR sales grew 6%; constant currency sales grew 5%; Q4 TMTT sales grew 88% to $105 million ...

The stock's rise snapped a three-day losing streak.

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Stratos Wealth Partners LTD. lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.0% ...

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...